Evidence map›Paper›PMID 41263834›Full record

ArticleBMJ open2025

Duffy-null variant and practical implications for patient care: a scoping review.

Edgar Asiimwe, Thye Peng Ngo, Elad Ziv, Andrew D Leavitt

Abstract readScoping Review
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Edgar AsiimweNational Clinician Scholars Program, UCSF, San Francisco, CA, USA edgar.asiimwe@ucsf.edu.ORCID http://orcid.org/0009-0001-7617-0677
Thye Peng NgoNational Clinician Scholars Program, UCSF, San Francisco, CA, USA.
Elad ZivDivision of General Internal Medicine at Mt. Zion, UCSF, San Francisco, California, USA.
Andrew D LeavittDivision of Hematology/Oncology, UCSF, San Francisco, CA, USA.

Funding

Evaluating the clinical implications for ACKR1/DARC associated neutropeniaR01HL170627 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Elad Ziv · 2023 to 2026
$2.6M
NHLBI NIH HHS R01 HL170627
6 · The paper itself

Abstract

objectiveTo evaluate and map research examining clinical associations with the Duffy-null variant.

designScoping review of the existing literature. DATA SOURCES: We conducted a systematic search of PubMed, Embase, CINAHL and Web of Science for studies published in English between 1 January 2000 and 25 June 2024. ELIGIBILITY: Studies were eligible for inclusion if they examined associations relevant to current standard clinical practice and met our protocol's inclusion criteria. DATA EXTRACTION: We extracted the following information from included studies: study year(s), patient population, sample size, study design, primary outcome and primary findings. Studies were grouped by outcome and synthesised in tabular and qualitative formats.

resultsA total of 2737 studies were screened, and 44 met our inclusion criteria. Most studies were observational, and the most common research question examined was the association with resistance to

Indexed as

Duffy Blood-Group SystemMalaria, VivaxReceptors, Cell SurfaceHumansACKR1 protein, humanDuffy Blood-Group SystemReceptors, Cell SurfaceCHEMOTHERAPYEPIDEMIOLOGYGENETICSHAEMATOLOGYMalariaReview

Identifiers

PMID41263834
PMCPMC12636991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.